Public health implications of antiretroviral therapy and HIV drug resistance

JAMA

Volumn 279, Issue 24, 1998, Pages 1977-1983

  Wainberg, Mark A ^a   Friedland, Gerald ^b  

^a MCGILL UNIVERSITY   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD; DRUG RESISTANCE; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; SECRETION; VIRUS MUTATION; VIRUS TRANSMISSION;

EID: 0032562985     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.24.1977     Document Type: Article

References (110)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-1734.
2. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-1559.
3. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1994;38:275-281.
4. Molla A, Komeyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
5. Frost SDW, McLean AR. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS. 1994;8:323-332.
6. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
7. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087-5094.
8. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246: 1155-1158.
9. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70:3763-3769.
10. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis. 1995;171:1172-1179.
11. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90: 5653-5656.
12. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991;65:4887-4892.
13. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
14. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
15. Erice A, Mayers DL, Strike DG, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328: 1163-1165.
16. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997; 175:1502-1506.
17. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994; 169:411-415.
18. de Ronde A, Schuurman R, Goudsmit J, vanden Hoek A, Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands. AIDS. 1996; 10:231-232.
19. Colgrove R, Pitt J, Chung PH, Welles S, Japour A. Selective vertical transmission of HIV-1 zidovudine resistance mutations. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 265.
20. Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. N Engl J Med. 1993;329:1835-1841.
21. R) HIV-1 in Switzerland, Australia, and the United States between 1988 and 1994. AIDS Res Hum Retroviruses. 1995;11(suppl 1): S162. Abstract 392.
22. Yerly S, Rakik A, Kinloch-de-Loes S, et al. Prévalence de la transmission de virus résistant à la zidovudine en Suisse. Schweiz Med Wochenschr. 1996;126:1845-1848.
23. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996. AIDS. 1997; 11:1184-1186.
24. Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS. 1997;11:835-836.
25. De Oliveira CF, Machado DM, Rawal BD, et al. Resistance to nucleoside-analog antiretroviral drugs among blood donors recently infected with HIV-1 and naive to antiretroviral treatment. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 672.
26. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute HIV infection. In: Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; St Petersburg, Fla; June 25-28, 1997. Abstract 103.
27. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122:401-408.
28. 3: a double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:561-571.
29. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331: 1173-1180.
30. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep. 1998;47(RR-4):1-43.
31. Vuthipongse P, Bhadrakom C, Chaisilwattana P, et al. Administration of zidovudine during last pregnancy and delivery to prevent perinatal HIV transmission - Thailand 1996-1998. MMWR Morb Mortal Wkly Rep. 1998;47:151-154.
32. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group protocol 076. J Infect Dis. 1998;177:557-564.
33. Frenkel LM, Wagner LE II, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20: 1321-1326.
34. Goudsmit JAAP, de Ronde A, Ho DD, et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol. 1996;70:5662-5664.
35. Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. J Infect Dis. 1994;169:611-614.
36. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol. 1996;70:3098-3107.
37. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses. 1996;12:107-115.
38. Poss M, Martin HL, Kreiss JK, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol. 1995; 69:8118-8122.
39. Hart C, Lennox JL, Evans-Strickfaden T, et al. HIV shedding occurs through the vaginal mucosa. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 714.
40. Larder B, Kemp S, Harrigan P. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269: 696-699.
41. Back N, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996;15:4040-4049.
42. Nijhuis M, Schuurman R, de Jong D, et al. Selection of HIV-1 variants with increased fitness during ritonavir therapy. In: Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; St Petersburg, Fla; June 25-28, 1997. Abstract 92.
43. Tersmette M, De Goede REY, Al BJM, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1998;62:2026-2032.
44. Salomon H, Gu Z, Gao Q, Nagai K, Hiscott J, Wainberg MA. Host cell dependence of human immunodeficiency virus type 1 drug resistance profiles and tissue culture selection patterns. Antiviral Chem Chemother. 1995;6:222-229.
45. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
46. Ho D, Neumann A, Perelson A, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
47. Coombs R, Welles S, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 1996; 174:704-712.
48. Holodniy M, Katzenstein D, Israelski D, et al. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest. 1991;88:1755-1759.
49. Katzenstein D, Holodniy M, Israelski D, et al. Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr. 1992;5:107-112.
50. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
51. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
52. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998; 279:930-937.
53. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
54. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
55. Wainberg M, Birch C. Phenotypic and genotypic resistance emergent in naive HIV-1 patients treated with combinations of reverse transcriptase inhibitors. In: Program and abstracts of the 3rd International Congress on Drug Therapy in HIV Infection; Birmingham, England; November 3-7, 1996. Abstract OP 7.2.
56. Vernazza L, Dollenmaier G, Gowland P, Roth F, Eron J, Fiscus S. Quantitative HIV-DNA detection in semen of HIV infected individuals: correlation with HIV-RNA and culture. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 190.
57. Xu C, Politch JA, Tucker L, Mayer KH, Seage GR 3rd, Anderson DJ. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis. 1997;176:941-947.
58. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis. 1997;176: 960-968.
59. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis. 1998;177:320-330.
60. Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS. 1994;8:1325-1329.
61. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998;72:617-623.
62. Rasheed S, Li Z, Xu D. Human immunodeficiency virus load: quantitative assessment in semen from seropositive individuals and in spiked seminal plasma. J Reprod Med. 1995;40:747-757.
63. Vernazza PL, Eron JJ, Fiscus SA. Sensitive method for the detection of infectious HIV in semen of seropositive individuals. J Virol Meth. 1996;56: 33-40.
64. Pomerantz R. HIV-1 in cervical and seminal fluid cells: potential reservoirs for HIV-1 in vivo. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Session 41, presentation S15.
65. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol. 1997;71: 6271-6275.
66. Evans JS, Dolan MJ, Walter EA, Anderson SA, Merritt T, Wegner S. Correlates of HIV-1 detection by viral load and culture in semen. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 189.
67. Uvin CU, Caliendo A, Russo R, et al. HIV-1 RNA levels in the genital tract of women on antiretroviral therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 713.
68. Hoesley C, Sfakianos G, Bragg S, Alvarez R, Squires K. Quantification of cervicovaginal lavage and plasma HIV-1 RNA in HIV-1 seropositive women. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 712.
69. Vernazza P, Gilliam B, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997;11:1249-1254.
70. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS. 1997;11: 987-993.
71. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS. 1997;11:F85-F93.
72. Cohen M, Hoffman I, Royce R, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet. 1997;349:1868-1873.
73. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet. 1997;350: 922-927.
74. Lennox J, Ellerbrock TV, Palmore M, et al. Effect of antiretroviral therapy on vaginal HIV RNA level. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; Washington, DC; January 22-26, 1997. Abstract 727.
75. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS. 1998;92:597-604.
76. Liuzzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS. 1996;10: F51-F56.
77. Eron JJ, Johnston D, Fiscus SA, Cohen MS, Alcorn T, Vernazza P. Emergence of HIV-1 resistance in seminal plasma of men on antiretroviral therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 678.
78. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis. 1994; 170:1292-1295.
79. Dyer JR, Gilliam BL, Eron JJ Jr, Grosso L, Cohen MS, Fiscus SA. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Meth. 1996; 60:161-170.
80. Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen: an isolated virus reservoir. Lancet. 1997;350:1141.
81. Albrecht H, Delrio C, Rimland D. Seminal viral load. AIDS. 1998;12:333-334.
82. Conway B, Montaner J, Cooper D, et al. Randomized, double-blind one year study of the immunologic and virologic effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naive, AIDS-free patients with CD4 200-600. In: Program and abstracts of the 3rd International Congress on Drug Therapy in HIV Infection; Birmingham, England; November 3-7, 1996. Abstract OP 7.1.
83. Moore RD, Keruly JC, Chaisson RE. Effectiveness of combination antiretroviral therapy in clinical practice. In: Program and abstracts of the 37th International Congress on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 28-October 1, 1997. Abstract 1-176.
84. + T cell changes in patients failing potent protease inhibitor therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 419.
85. Mayers D. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy. In: Program and abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; St Petersburg, Fla; June 25-28, 1997. Abstract 80.
86. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335:1621-1629.
87. CDC provisional PHS recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45: 468-472.
88. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection drug use. N Engl J Med. 1997;336:1097-1100.
89. Lee T-H, Sakahara N, Fiebig E, Busch MP, O'Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J AIDS. 1996;12:427-428.
90. Operskalski EA, Stram DO, Busch MP, et al. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients: Transfusion Safety Study Group. Am J Epidemiol. 1997;146:655-661.
91. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophiliac patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:42-45.
92. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission: Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;154:1971-1976.
93. Kravcik S, Victor G, Houston S, et al. The effect of protease inhibitor therapy and "undetectable" viral load on perceived risk of HIV transmission and need for safer practices. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 187.
94. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979:11-27.
95. Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979.
96. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract. 1990;40:114-116.
97. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev. 1992;49:435-454.
98. Epstein LH. The direct effects of compliance on health outcome. Health Psychol. 1984;3:385-393.
99. Horwitz R, Viscoli C, Berkmann L, et al. Treatment adherence and risk of death after myocardial infarction. Lancet. 1990;336:542-545.
100. Corelli RL, Guglielmo BJ, Kapusnik-Uner JE, et al. Medication usage patterns in patients with human immunodeficiency virus infections: a comparison of patient-reported medication usage with medical chart review. Pharmacoepidemiology. 1991;25:1374-1378.
101. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439-447.
102. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-502.
103. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
104. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995; 37:261-269.
105. Broers B, Morabia A. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med. 1994;154:1121-1127.
106. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385-391.
107. Bayer R. Ethical challenges posed by new advances in the anti-retroviral treatment of HIV disease. In: Praag EV, Fernyak S, Katz AM, eds. The Implications of Antiretroviral Treatments. Geneva, Switzerland: World Health Organization; 1997: 95-101.
108. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1994;100:258-268.
109. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386.
110. Williams A, Friedland GH. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9:51-58.